{"filing":{"accession_number":"0001193125-26-430621","cik":"0001783183","ticker":"PHAT","company_name":"Phathom Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"d437998d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526430621/d437998d8k.htm"},"events":[{"id":37684,"run_id":34729,"accession_number":"0001193125-26-430621","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"summary":"BDR Pharmaceuticals has filed suit against the FDA in the U.S. District Court for the District of Columbia challenging FDA's grant of 10 years of NCE exclusivity for Phathom's VOQUEZNA product. This is material litigation that directly threatens Phathom's regulatory exclusivity and competitive position; an adverse outcome would permit generic competition earlier than anticipated and materially harm the company's business and financial prospects, as explicitly acknowledged in the forward-looking statements risk factors.","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42471,"accession_number":"0001193125-26-430621","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"BDR Pharmaceuticals has filed suit against the FDA in the U.S. District Court for the District of Columbia challenging FDA's grant of 10 years of NCE exclusivity for Phathom's VOQUEZNA product. This is material litigation that directly threatens Phathom's regulatory exclusivity and competitive position; an adverse outcome would permit generic competition earlier than anticipated and materially harm the company's business and financial prospects, as explicitly acknowledged in the forward-looking statements risk factors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:02:03.192748+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42471,"accession_number":"0001193125-26-430621","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.95,"reasoning":"BDR Pharmaceuticals has filed suit against the FDA in the U.S. District Court for the District of Columbia challenging FDA's grant of 10 years of NCE exclusivity for Phathom's VOQUEZNA product. This is material litigation that directly threatens Phathom's regulatory exclusivity and competitive position; an adverse outcome would permit generic competition earlier than anticipated and materially harm the company's business and financial prospects, as explicitly acknowledged in the forward-looking statements risk factors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:02:03.192748+00:00","company_name":"Phathom Pharmaceuticals, Inc.","ticker":"PHAT","filing_date":"2026-10-23"}]}